The Genetic Homogeneity of CAPOS Syndrome: Four New Cases With the c.2452G>A (p.Glu818Lys) Mutation in the ATP1A3 Gene.
Pediatr Neurol. 2016 Mar 17;
Authors: Maas RP, Schieving JH, Schouten M, Kamsteeg EJ, van de Warrenburg BP
Abstract
BACKGROUND: The clinical syndrome of cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS) was first described 20 years ago, but it was only recently that whole exome sequencing unveiled the causative mutation in the ATP1A3 gene. We here present four patients from the seventh and eighth family identified worldwide, provide a critical review of all cases published thus far, and speculate about the pathophysiologic processes underlying the acute neurological manifestations.
CLINICAL OBSERVATIONS: The individuals presented here experienced one to three paroxysmal, short-lasting episodes in childhood with cerebellar symptoms and signs, hypotonia, ophthalmoparesis, motor weakness, areflexia, and/or lethargy that were consistently associated with febrile illness. An underlying c.2452G>A mutation in the ATP1A3 gene was found in all four cases. Besides the persisting CAPOS features, other possibly related sequelae included dystonia, myoclonus, and emotional and behavioral changes. After initiation of acetazolamide in two patients, no further episodes occurred.
CONCLUSION: Targeted sequencing of the ATP1A3 gene is recommended in children exhibiting paroxysmal, fever-induced ataxia and in adults with a more or less stationary or slowly progressive cerebellar syndrome since childhood accompanied by mixed combinations of areflexia, pes cavus, profound visual impairment, and/or sensorineural hearing loss. Similar to some other types of episodic ataxia, acetazolamide may be considered in patients with CAPOS syndrome to prevent or attenuate bouts of ataxia, but this requires further study.
PMID: 27091223 [PubMed - as supplied by publisher]
from #ENT via xlomafota13 on Inoreader http://ift.tt/26eKna2
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου